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A B S T R A C T
Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV in-
fection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in
approximately 400,000 deaths annually. Effective direct-acting antiviral agents (DAAs) have been developed
and are currently used for HCV treatment targeting the following three proteins: NS3/4A proteinase that cleaves
the HCV polyprotein into various functional proteins, RNA-dependent RNA polymerase (designated as NS5B),
and NS5A, which is required for the formation of double membrane vesicles serving as RNA replication orga-
nelles. At least one compound inhibiting NS5A is included in current HCV treatment regimens due to the high
efficacy and low toxicity of drugs targeting NS5A. Here we report fluorene compounds showing strong inhibitory
effects on GT 1b and 3a of HCV. Moreover, some compounds were effective against resistance-associated var-
iants to DAAs. The structure-activity relationships of the compounds were analyzed. Furthermore, we in-
vestigated the molecular bases of the inhibitory activities of some compounds by the molecular docking method.
1. Introduction
About 71 million people are infected with Hepatitis C virus (HCV)
worldwide, causing approximately 400,000 deaths each year. Chronic
HCV infection is a major causative agent of chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma (HCC) (Khullar and Firpi,
2015). HCV is an enveloped RNA virus of the Flaviviridae family,
comprising of a 9.6 kb (+)-sense single strand RNA. To date, the HCV
strain has been classified into seven genotypes (GTs) and about 70
subtypes. According to recent estimation, genotype (GT) 1 is the most
prevalent (46.2%), followed by GT 3 (30.1%) (Messina et al., 2015).
Even though pegylated interferon-α (pegIFN-α) combined with riba-
virin was previously the most commonly used treatment, combinations
of direct-acting antiviral agents (DAAs) against HCV are currently the
standard for HCV therapy (Zhang et al., 2016). The major targets of
DAAs are NS3/4A protease, NS5B RNA-dependent RNA polymerase,
and NS5A (which participates in viral genome replication and en-
capsidation) (Pietschmann and Brown, 2019). This study focused on the
development of anti-HCV compounds targeting NS5A.
NS5A of HCV is a multi-functional protein participating in viral RNA
replication, virus assembly, and virion particle release. It also influ-
ences many cellular processes such as apoptosis, stress-responses, im-
mune responses, and cell cycle, although no enzymatic activity of NS5A
has been reported (He et al., 2006; Huang et al., 2007). NS5A, com-
posed of 450 amino acids, consists of an amphipathic alpha helix region
(AH) at the N-terminus, followed by three domains I, II, and III. How-
ever, a recent study conjectured that the domains II and III are not
clearly distinct as previously suggested (Badillo et al., 2017). Four X-ray
crystal structures of the NS5A domain I, excluding the AH region, have
been reported (Lambert et al., 2014; Love et al., 2009; Tellinghuisen
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et al., 2005), and the structure of the AH region was separately de-
termined by NMR (Penin et al., 2004). However, the three-dimensional
structure of the full-length NS5A domain I, including the AH region, has
yet to be reported.
Sequence analyses of drug resistant variants revealed two regions in
NS5A that affect the activity of NS5A inhibitors (Fridell et al., 2010;
Sorbo et al., 2018; Teraoka et al., 2018). The first region is near amino
acid 31 of NS5A, which corresponds to the flexible linker between the
AH region and the rigidly structured core region of domain I. Various
changes around this region contribute to drug resistance. However, it is
unclear how anti-HCV compounds associate with NS5A since the
structure of this flexible linker region is unknown, and the structure of
an NS5A-drug complex has never been solved (Lambert et al., 2014;
Love et al., 2009; Tellinghuisen et al., 2005). The second region is near
amino acid 93 of NS5A within the rigid core of domain I. Four different
structures of the rigid core of domain I have been reported. Its overall
folding structure was similar in all reports and predicted as dimeric
forms. However, the reported contacting regions of the domain I dimers
differed from each other (Lambert et al., 2014; Love et al., 2009;
Tellinghuisen et al., 2005). Therefore, it is unclear which dimer form of
NS5A functions in HCV replication and/or viral particle assembly in
cells, providing an additional difficulty in predicting the binding site(s)
of anti-HCV drugs targeting NS5A.
Anti-HCV drugs targeting NS5A are highly effective and well tol-
erated. However, NS5A inhibitors usually have a low genetic barrier for
resistance-associated variants (RAVs) development in single compound
treatment conditions (Lawitz et al., 2016). We previously reported new
anti-HCV compounds targeting NS5A (Bae et al., 2015). Among them,
compound 43 containing a 9,9-difluoro-substituted fluorene skeleton
showed a very high inhibitory effect on wild type and daclatasvir-re-
sistant mutant L31V (Leu31Val) of GT 1b HCV (Bae et al., 2015).
However, it was not highly effective against the major daclatasvir-re-
sistant mutant Y93H (Tyr93His) or double mutant L31V+Y93H
(Table 1). Here, we report a new series of NS5A inhibitors containing a
fluorene proline-amide skeleton showing strong inhibitory effects not
only on both GT 1b and 3a HCV, but also on daclatasvir-resistant mu-
tants. Moreover, the NS5A inhibitors showed low cytotoxicity. Finally,
we describe structure-activity relationships (SAR) between the in-
hibitors and drug resistance mutants through in vitro efficacy tests and
in silico docking studies.
2. Materials and methods
2.1. Compounds
Testing compounds were synthesized as previously described (Bae
et al., 2015; Hee Sun Kim, March, 2019). The synthesized compound
was dissolved in dimethyl sulfoxide (DMSO) at a concentration of
10 mM. MK-5172 (grazoprevir) and GS5816 (velpatasvir) were pur-
chased from Shanghai Heat-biochem, BMS-790052 (daclatasvir) and
Geneticin (G418) were purchased from Selleckchem, and AG Scientific,
respectively.
2.2. Analysis of the compound structure and purity
HPLC analyses were carried out using an Agilent HP1100 system
(Santa Clara, CA, USA), composed of an auto sampler, quaternary
pump, photodiode array detector (DAD), and HP Chemstation software.
The separation was carried out on a poroshell 120 EC-C18 column
50 × 4.6 mm, 2.7 mm with acetonitrile (A), 0.1% TFA in water (B), as a
mobile phase at a flow rate of 1 ml/min at 20 °C. Method: 5% A and
95% B (0 min), 50% A and 50% B (15 min), 95% A and 5% B (24 min),
95% A and 5% B (25 min), 5% A and 95% B (26 min), 5% A and 95% B
(27 min). All materials were purchased from commercial suppliers and
used without further purification unless otherwise noted (Fig. S1).
2.3. Construction of plasmids and in vitro transcription of RNA
Plasmid pNK5.1-Gluc was constructed by inserting the Gaussia lu-
ciferase (Gluc) gene into plasmid pNK5.1/Con1 (Krieger et al., 2001).
To construct pNK5.1-Gluc, we generated a new Asc1 restriction enzyme
site between the HCV IRES and neomycin phosphotransferase region of
pNK5.1 by site-directed mutagenesis. A DNA fragment containing the
2A protease gene of foot-and-mouth-disease virus (FMDV) at both N-
and C-terminal sides of the Gaussia luciferase gene was amplified by
PCR. The amplified 2A-Gluc-2A DNA fragment containing Asc1 sites at
both ends was digested with the Asc1 enzyme and ligated into the
pNK5.1 containing Asc1 site (Fig. 1A). Plasmids encoding GT 1b re-
plicons with drug-resistant mutations (L31V, Y93H, and L31V+Y93H)
in NS5A were generated by site-directed mutagenesis using pNK5.1-
Gluc as a template.
Plasmid pJC1-Gluc was constructed by inserting the 2A-Gluc-2A
DNA fragment between the P7 and NS2 region of pJC1 (Phan et al.,
2009; Pietschmann et al., 2006). A new Asc1 restriction enzyme site
was inserted between the P7 and NS2 region of pJC1 by site-directed
mutagenesis. The 2A-Gluc-2A DNA was digested using the Asc1 enzyme
and ligated into the Asc1 site-containing pJC1 (Fig. 1A). Plasmid pS52-
Feo, encoding the GT 3a subgenomic replicon, was kindly provided by
Dr. Charles M. Rice (The Rockefeller university) (Saeed et al., 2012).
To synthesize GT 1b replicon RNA, in vitro transcription was per-
formed using T7 polymerase with Sca1-linearized pNK5.1-Gluc DNA.
To synthesize GT 2a infectious RNA, in vitro transcription was per-
formed using T7 polymerase with Xba1-linearized pJC1-Gluc. To syn-
thesize GT 3a replicon RNA, in vitro transcription was performed using
T7 polymerase with pS52-Feo linearized by Xba1.
2.4. Cell lines and cell culture
Huh 7.5.1 cells were cultured in Dulbecco's Modified Eagle's
medium (DMEM, Gibco™) containing antibiotics (100 U/ml penicillin
and 10 μg/ml streptomycin) supplemented with 10% fetal bovine
serum (FBS, PEAK, Inc.) in a humidified 6.0% CO2 incubator at 37 °C.
Huh 7.5.1 cells containing a bicistronic HCV replicon NK5.1-Gluc (GT
1b) and S52-Feo (GT 3a) were used to test the anti-HCV activities of
chemicals (Fig. 1A). Replicon RNA (30 μg) was transfected into
Huh7.5.1 cells. The cells were cultured in DMEM with G418 (0.5 mg/
ml, Calbiochem) for selective cultivation of cells containing the HCV
replicon. After selection, replicon-containing cells were cultured in
DMEM containing antibiotics (100 U/ml penicillin, 10 μg/ml strepto-
mycin, and 0.5 mg/ml G418) supplemented with 10% FBS (PEAK, Inc.).
2.5. Virus production
In vitro transcribed HCV RNAs were electrophorated into Huh
7.5.1 cells as described previously (Kim et al., 2011). The transfected
cells were cultured for 3 days. Following, the culture media containing
Table 1
Effects of compound 43 on various HCV replicons.
EC50 (nM) a
GT 1b (NK5.1) 0.003
GT 2a (Jc1) 0.059
GT 3a (S52) 0.014
GT 1b L31V 0.12
GT 1b Y93H 2.3
GT 1b L31V+Y93H >1,000
CC50b >20,000
a The values depict mean and standard deviation.
EC50, Effective concentration 50%.
b CC50, Cytotoxicity concentration 50%. Results from
three independent experiments in duplicate.
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Fig. 1. Assay systems to investigate anti-HCV activities of compounds and molecular structure of compound 43 and its modification sites. (A) Schematic
diagrams of subgenomic replicons NK5.1-Gluc and S52-Feo, and an infectious HCV clone Jc1-Gluc for testing anti-HCV activities of compounds against GT 1b, 3a, and
2a HCVs, respectively. (B) Molecular structure of compound 43 (upper panel). Modifications of compound 43 at several sites (designated as R, Y, and Z) were
executed to develop compounds having higher activities to GT 3 HCV and RAVs of HCV.
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virion particles (HCVcc) were collected for 7 days and filtered through a
0.45 μm pore size filter.
2.6. Measurement of anti-HCV activities of compounds using HCVcc
Huh 7.5.1 cells were inoculated with JC1-Gluc virus (Kim et al.,
2011; Pietschmann et al., 2006). Four hours after viral inoculation,
HCV-infected Huh 7.5.1 cells were cultured with media containing se-
rially diluted inhibitors. Three days post-chemical treatment, culture
media were harvested, and Gaussia luciferase activities in the media
were measured using a Renilla luciferase assay system (Promega) ac-
cording to the manufacturer's protocol. Luciferase activities were nor-
malized to those obtained from mock-treated (0.1% DMSO) cells. Fur-
ther, a four-parameter logistic calculation was used to calculate EC50
and statistical values in the SigmaPlot Program software (Systat Soft-
ware Inc.).
2.7. Measurement of anti-HCV activities of compounds using HCV replicon
Replicon-containing cells were seeded on a 12-well plate
(5 × 104 cells per well). One day after cell seeding, culture media were
changed with fresh media containing serially diluted compounds. The
cells were further cultured for 3 days. Following, culture media were
collected to measure activity of Gaussia luciferase secreted from cells
containing NK5.1-Gluc replicon. Gaussia luciferase activity was mea-
sured using a Renilla luciferase assay system (Promega). To measure
firefly luciferase activity in cells containing S52-Feo replicon, cells were
harvested and lysed after compound treatments for 3 day. Firefly lu-
ciferase activities in cell lysates were measured by a firefly luciferase
assay system (Promega) according to the manufacturer's protocol. The
luciferase activities were normalized to those obtained from mock-
treated (0.1% DMSO) cells. Further, a four-parameter logistic calcula-
tion was used to calculate EC50 and statistical values in the SigmaPlot
Program software (Systat Software Inc.).
2.8. Colony formation assay
Huh 7.5.1 cells containing a HCV replicon (NK5.1-Gluc or S52-Feo)
were used for colony formation assays. Replicon-containing cells were
seeded on a 6-well plate (5 × 104 cells per well). At 16 h after cell
seeding, culture media were changed with fresh media containing se-
rially diluted compounds without G418. The cells were cultured for 5
days. Subsequently, the cells were split into new 6-well plates to about
20% confluence. The cells were further cultured for 5 days and split into
new 6-well plates to about 20% confluence. Culture media were
changed with DMEM containing 1 mg/ml G418, refreshing every 2–3
days. Two weeks after selection initiation, cells were stained with
Crystal violet solution (1% formaldehyde, 1% methanol, and 0.5 g
Crystal violet) for 20 min and washed with PBS. Images were captured
by an Amersham™ Imager 600 (GE healthcare) following plate drying.
2.9. Sequencing of replicon RNAs
After colony formation, total RNAs were isolated from cells using
TRIzol reagent (Invitrogen). cDNAs were synthesized using a reverse
transcriptase (Promega), and the DNA fragments corresponding to HCV
NS5A were amplified by PCR with a pair of primers (forward primer:
5′-GGTACCAGCGGCGATTGGCTGCG-3′, reverse primer: 5′-TCTAGAGC
AGCAGACCACGCTCT-3′). The amplified DNA fragments were inserted
into pcDNA 3.1 vector (Invitrogen) and transformed into E. coli. After
sequencing the inserted DNAs, the sequences were analyzed by DS gene
program.
2.10. Cytotoxicity test
Compound cytotoxicity was assessed using a ToxiLight™ (Lonza)
cytotoxicity assay kit, according to the manufacturer's protocol. In brief,
Huh 7.5.1 cells were seeded on 24-wells plate (2 × 104 cells per well).
One day after cell seeding, culture media were changed with fresh
DMEM containing serially diluted compounds. The cells were further
cultured for 3 days. Following, culture media were collected and cen-
trifuged to remove cell debris (12,000 rpm, 4 °C, 10 min). Finally, cy-
totoxicity level was measured by a luminescence reader (Victor 3,
Perkin Elmer™) using a ToxiLight™ kit.
2.11. hERG ligand binding assay
The hERG ligand binding assay was performed using a Predictor™
hERG fluorescence polarization assay kit (cat no. PV5365) according to
the manufacturer's directions. In brief, 5 μl of test compound, 10 μl of
membrane, and 5 μl of tracer were applied to a 384-well plate. The
plate was covered with aluminum foil to block light and incubated for
2–3 h at room temperature. Fluorescence polarization of the hERG red
tracer was measured using a TECAN plate reader (Infinite M1000 pro).
2.12. Cytochrome P450 (CYP) inhibition assay
Testing compounds (10 μM) were incubated with human liver mi-
crosomes (0.25 mg/ml) and probe substrate cocktail [Phenacetin
(50 μM), Diclofenac (10 μM), S-mephenytoin (100 μM),
Dextromethorphan (5 μM), and Midazolam (2.5 μM)] in 0.1 M phos-
phate buffer for 5 min at 37 °C. The probe substrates were used to
determine activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and
CYP3A4, respectively. NADPH generation solution was added to the
mixtures and further incubated for 15 min at 37 °C. The reactions were
stopped by adding acetonitrile. The reaction products were centrifuged
at 14,000 rpm for 5 min at 4 °C. Following, the supernatants were in-
jected into a LC-MS/MS system (Shimadzu Nexera XR system and TSQ
vantage (Thermo)). Finally, amounts of remaining probe substrates
were measured by LS-MS/MS analyses.
2.13. Molecular modeling
Two three-dimensional structures of HCV NS5A domain I were
downloaded from protein data bank (PDB) as open (PDB code: 1ZH1)
and closed (PDB code: 3FQQ) forms (Love et al., 2009; Tellinghuisen
et al., 2005). Since both open and closed forms of NS5A structures do
not contain information on the N-terminal 1–31 amino acid residues
that are likely to participate in association with anti-HCV compounds,
we modeled the missing component (UniProtKB = Q9WMX2) using
Discovery Studio Client 2018 suite of package (2018) and HCV GT 1a
structure (PDB code: 1R7G) as a template (Penin et al., 2004). The
modeled open and closed forms of NS5A structures were generated
using the protein preparation wizard (Sastry et al., 2013) of the maestro
utility in Schrödinger 2017-4 suites package [Schrödinger Release
2017-4: LLC, New York, NY 2017] at the default setting. Chemical
structures of the ligands were sketched using ChemDraw Professional
16 and imported to the maestro Ligprep module. The ligand models
were generated at the default setting of Ligprep module and saved as
SDF format. Binding site information was obtained from previous re-
ports, in which L31 and Y93 were mentioned as sites for drug-resistant
mutations (Sorbo et al., 2018). Subsequently, the grid was assigned at
the geometric center of residues L31 and Y93 of both chains of NS5A in
open and closed form models. Grid expansion by 8 Å in the XYZ di-
rection was executed to fit the ligand inside the pocket. Standard pre-
cision (SP) docking algorithm implemented inside the GLIDE docking
module (Friesner et al., 2004) was used for further docking study of
compounds inside the NS5A models. Fifty docking solutions were
generated for each ligand and ranked according to more negative glide
docking score. Tighter ligand binding inside the protein was reflected
by negative glide docking score. All figures were rendered using Dis-
covery Studio Client 2018 and Pymol 2.2.0 (http://www.pymol.org)
H.S. Kim, et al. Antiviral Research 174 (2020) 104678
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visualization tools.
3. Results
3.1. Effects of core structure of fluorene compounds on HCV replication
To determine the EC50 of compounds on HCV replication, HCV cell
culture (HCVcc) and HCV replicon systems were used (Fig. 1A) as de-
scribed in materials and methods (Blight et al., 2000; Kim et al., 2011;
Krieger et al., 2001; Lohmann et al., 1999; Pietschmann et al., 2006;
Saeed et al., 2012). In order to improve properties of compound 43
(Table 1), which were reported previously (Bae et al., 2015), we
modified residues at positions R, Y, and Z (Fig. 1B). First, we in-
vestigated the effect of alkyl chain length at the C9 position of the
fluorene core (R) on HCV GTs 1b (NK5.1), 2a (JC1), and 3a (S52). In
this study, we used the same linker (L-proline) and cap region (N-
methoxycarbonyl phenylglycine) of the compounds (Fig. 1B). As the
length of alkyl chain at the C9 position increased, the inhibitory effects
of compounds on HCV GT 1b and 3a gradually increased. For com-
pound 4, the EC50 value reached 3–7 pM range (Table 2). However, the
length of alkyl chain did not linearly correlate with the EC50 value of
HCV GT 2a (Table 2).
Moreover, we tested the effects of compounds on HCV GT 1b con-
taining the major daclatasvir-resistant variants such as L31V (single
mutant), Y93H (single mutant), and L31V+Y93H (double mutant).
Efficacy of the compounds on RAVs gradually increased as the length of
the alkyl chain increased, reaching maximal effectiveness with com-
pound 3, which contains a 4-carbon chain (Table 3). As a result,
compounds containing 9,9-dibutylfluorene and 9,9-dipentylfluorene
(compounds 3 and 4, respectively) showed very strong inhibitory ef-
fects on wild type and RAV L31V of GT 1b HCV (Table 2).
3.2. Effects of the proline structure of fluorene compounds on HCV
replication
To investigate the effect of proline residues of compounds 3, we
fixed the core residue with 9,9-dibutylfluorene (Table 3) and assessed
the effect of the C4 position of L-proline residues (Fig. 1B, Y and Z
positions) on various GTs of HCV and RAVs of GT 1b. As shown in
Table 2, the parental compound (compound 3) showed very strong anti-
HCV effects against GT 1b and GT 3a, but weak effects against GT 2a
(Table 3). Moreover, compounds 3 and 4 were very effective on RAV
L31V of GT 1b, but not highly effective against both RAVs Y93H and
L31V+Y93H (Table 2). Interestingly, modifications of the C4 position
of proline residues (Y and Z positions in Fig. 1B) showed dramatic ef-
fects on RAVs Y93H and L31V+Y93H (Table 3 and Table S1). Parti-
cularly, substitutions of proline to 4-spirocyclic ketal-L-proline (com-
pounds 6, 8, and 9) or 4-hydroxyl-L-proline (compound 10) improved
the efficacies of compounds against RAVs Y93H and L31V+Y93H
(Table 3).
3.3. Selection of RAVs after anti-HCV compound treatment
We investigated genetic resistance barriers of compounds by mea-
suring colony-forming efficiencies of Huh7.5.1 cells containing the GT
1b or GT 3a replicon after anti-HCV compound treatments at various
concentrations for 10 days (Fig. 2A) (Wang et al., 2012). After com-
pound treatments, the cells were split in new plates and treated with
G418 (1 mg/ml) for 14 days in the absence of anti-HCV compound to
select replicon-containing cells. The cell colonies were visualized by
Crystal violet staining (Fig. 2A) or maintained for additional in-
vestigations. We performed colony-forming assays with compounds 3,
9, 10, and reference compounds using replicons GT 1b (Fig. 2B, Fig.
S2A) and GT 3a (Fig. 2C, Fig. S2B). All of the compounds, including the
Table 2
Effects of core structure of fluorene compounds on various HCV replicons.
EC50 (nM) a CC50b
No. R GT 1b (NK5.1) GT 2a (JC1) GT 3a (S52) GT 1b L31V GT 1b Y93H GT 1b L31V+Y93H
1 0.071 ± 0.015 0.70 ± 0.05 0.336 ± 0.019 0.200 ± 0.101 18.30 ± 0.01 > 100 >20,000
2 0.138 ± 0.037 14.5 ± 1.50 0.311 ± 0.161 0.148 ± 0.015 4.60 ± 1.60 > 100 >20,000
3 0.002 ± 0.001 1.24 ± 0.20 0.016 ± 0.008 0.004 ± 0.000 0.88 ± 0.11 41.4 ± 29.5 > 20,000
4 0.003 ± 0.000 5.90 ± 4.90 0.007 ± 0.006 0.002 ± 0.002 2.30 ± 0.30 47.8 ± 32.7 > 20,000
a The values depict mean and standard deviation. EC50, Effective concentration 50%.
b CC50, Cytotoxicity concentration 50%. Results from three independent experiments in duplicate.
Table 3
Effects of the proline structure of fluorene compounds with 9,9-dibutylfluorene core on various HCV replicons.
EC50 (nM) a CC50b
No. R Y Z GT 1b (NK5.1) GT 2a (JC1) GT 3a (S52) GT 1b L31V GT 1b Y93H GT 1b L31V+Y93H
3 0.002 ± 0.000 1.2 ± 0.2 0.016 ± 0.007 0.003 ± 0.0002 0.88 ± 0.10 41.4 ± 29.5 > 20,000
5 0.004 ± 0.000 0.73 ± 0.07 0.029 ± 0.012 0.004 ± 0.001 0.78 ± 0.10 14.8 ± 6.6 > 20,000
6 0.006 ± 0.001 1.6 ± 0.4 0.030 ± 0.004 0.007 ± 0.007 0.08 ± 0.03 1.04 ± 0.1 > 20,000
7 0.014 ± 0.001 0.65 ± 0.02 0.082 ± 0.022 0.004 ± 0.001 0.15 ± 0.25 2.2 ± 0.3 > 20,000
8 0.022 ± 0.009 1.4 ± 0.6 0.079 ± 0.01 0.003 ± 0.003 0.024 ± 0.002 0.44 ± 0.06 > 20,000
9 0.005 ± 0.001 5.6 ± 0.6 0.354 ± 0.006 0.007 ± 0.002 0.045 ± 0.001 0.033 ± 0.003 >20,000
10 OH(R) OH(R) 0.029 ± 0.008 3.5 ± 0.12 0.133 ± 0.012 0.025 ± 0.002 0.029 ± 0.002 0.058 ± 0.002 >20,000
a The values depict mean and standard deviation. EC50, Effective concentration 50%.
b CC50, Cytotoxicity concentration 50%. Results from three independent experiments in duplicate.
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reference inhibitors (daclatasvir and velpatasvir), showed higher effi-
cacy to GT 1b than GT 3a, which was indicated by the number of co-
lonies after compound treatments and EC50 values (compare Fig. 2B
with 2C, and S2A with S2B). Treatments of compounds 9 and 10 for 10
days completely inhibited colony formation of Huh7.5.1 cells
containing a GT 1b replicon at 500 pM or higher concentrations
(Fig. 2B). Interestingly, compound 3 showed a higher inhibitory effect
than compound 10 against GT 3a at a low concentration (75 pM);
however, compound 10 showed higher inhibitory effect than compound
3 at high concentrations (7.5 nM or higher) in drug-resistant colony-
Fig. 2. Effects of fluorene compounds on colony formations of Huh 7.5.1 cells containing subgenomic replicons. (A) Schematic diagram of colony formation
assay. Colony formation assays were performed as described in Materials and Methods. (B) Effects of compounds 3, 9, and 10 on the colony formation of Huh
7.5.1 cells containing the GT 1b replicon NK5.1-Gluc. (C) Effects of compounds 3, 9, and 10 on the colony formation of Huh 7.5.1 cells containing the GT 3a replicon
S52-Feo.
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forming assays (Fig. 2C, also see below).
3.4. Mutations in RAVs selected during inhibitor treatments
We analyzed mutations in the HCV replicon RNAs (GT 3a) that were
selected during treatments of inhibitors targeting NS5A. We used dif-
ferent concentrations of inhibitors [compounds 3 (750 pM and 750 nM)
and 10 (75 pM and 750 pM), daclatasvir (75 nM), and velpatasvir
(7.5 nM)] since each compound has different upper concentration limit
allowing colony formation (Fig. 2, Fig. S2). We used the selection
concentrations near the upper limits of individual compounds produ-
cing enough colonies to identify various mutations that provided strong
resistance against the compounds.
As reported previously (Fridell et al., 2010; Lawitz et al., 2016),
either substitution of tyrosine to histidine at amino acid 93 (Y93H) or
substitution of leucine to valine at amino acid 31 (L31V) in NS5A was
the major mutations providing resistance against daclatasvir or velpa-
tasvir, respectively (Fig. S3). Several other mutations in various parts of
NS5A domain 1 were also observed in most of RAVs (Fig. S3). Double
mutation at L31 and Y93 was not found in velpatasvir-treated cells, and
the double mutation [Y93H and substitution of leucine to phenylala-
nine at amino acid 93 (L31F)] was found only once in daclatasvir-
treated cells. In contrast, the major RAVs of HCV replicons in compound
3 (750 pM)-treated cells contained substitutions of both L31V and
Y93H (Fig. 3A). Moreover, most of the RAVs had an additional sub-
stitution of methionine to threonine at amino acid 79 (M79T) in NS5A.
One of the RAVs had a substitution of leucine to phenylalanine at amino
acid 31 (L31F) and an additional substitution of threonine to isoleucine
(T95I) instead of L31V, Y93H, and M79T mutations in NS5A (Fig. 3A).
Furthermore, all RAVs of HCV replicons selected at higher concentra-
tion of compound 3 (750 nM) contained Y93H substitution. One or two
additional mutations (A25T, L74R, and L31V + M79T) were observed
in all RAVs selected at 750 nM of compound 3 (Fig. S4A). The results
indicated that Y93H substitution is the key mutation providing re-
sistance against compound 3, and that additional mutations are re-
quired for strong resistance against compound 3 at high concentration.
Interestingly, L31V and L31F substitutions were the dominating mu-
tations of RAVs selected by treatment of compound 10 (75 pM or 750
pM) (Fig. S4B, Fig. 3B, respectively). Occasionally, however, substitu-
tion of threonine to alanine at amino acid 21 (T21A) and substitution of
lysine to arginine at amino acid 20 (K20R), both of which reside in the
amphipathic helix close to the leucine 31, were observed in RAVs se-
lected by compound 10 at 75 pM (Fig. S4B). No Y93H substitution was
observed from the RAVs selected by compound 10 at 75 pM (Fig. S4B).
However, Y93H substitution was found in a few RAVs selected by
compound 10 at 750 pM (Fig. 3B). The results indicated that sub-
stitutions in or around the amphipathic helix are the main mutations
providing resistance against compound 10.
Through the analyses of the RAVs, we conjectured that the muta-
tions contributing to resistances to different compounds varies sig-
nificantly even though the sites of frequent mutations are generally
fixed. This might indicate that a specific mutation(s) providing strong
resistance to a specific compound might not significantly affect the
susceptibility to a compound with a high genetic barrier for RAV de-
velopment. Indeed, the pools of replicon containing cells (GT 3a) se-
lected by either daclatasvir (75 nM) or velpatasvir (7.5 nM) were highly
susceptible to compound 10 (EC50s were 0.58 nM and 0.74 nM, re-
spectively) (Fig. 3C). The results were consistent with the higher dif-
ficulties of GT 3a RAV generations by compound 10 than those by
daclatasvir and velpatasvir (compare Fig. 2C with Fig. S2).
Effects of co-treatment of grazoprevir (a NS3/4A proteinase in-
hibitor) and fluorene compounds on HCV replication.
We further analyzed compound 10 containing 4-hydroxyl-L-proline
and compound 3 containing unmodified L-proline since compound 10
showed the highest genetic resistance barrier for GT 3a and strong in-
hibitory effects against both GT 1b and GT 3a. The effects of co-
treatment of these compounds with grazoprevir were investigated since
standard anti-HCV therapy includes two or more drugs to minimize
RAV generation. EC90 concentrations of grazoprevir (2 nM and 100 nM
for GT 1b and GT 3a, respectively) were used in combination with the
indicated amounts of anti-NS5A compounds for 10 days. Huh7.5.1 cells
containing drug-resistant replicons were selected by G418 treatment.
Single treatments of 2 nM and 100 nM of grazoprevir on GT 1b and GT
3a, respectively, resulted in significant cell growth (top panel in Fig. 4A
and 4B). In contrast, no colony formation was observed from GT 1b
replicon-containing cells treated with 2 nM of grazoprevir together with
125 pM (or higher concentration) of compounds 3 and 10. The data
indicated that compounds 3 and 10 were very effective against GT 1b
when co-treated with grazoprevir.
Co-treatment of grazoprevir with compounds 3 and 10 showed
various antiviral activities against the GT 3a replicon. No colony for-
mation was observed with 100 nM of grazoprevir (EC90 value) and 75
pM of compound 3 or 750 pM of compound 10 (Fig. 4B) co-treatment.
Further, co-treatment of grazoprevir with compound 3 eliminated
colony formation at lower concentration than that with compound 10
(Fig. 4B). This effect is likely attributed to the lower EC50 value of
compound 3 than compound 10 against GT 3a (Table 3). These data
indicated that co-treatment of anti-NS3/4A (grazoprevir) and anti-
NS5A compounds was much more effective than mono-treatment of
either anti-NS3A/4A or anti-NS5A compounds (Fig. 2B) for complete
elimination of HCV RNA in cells.
To characterize co-treatment effects, we calculated combination
index (CI) values using the Compusyn freeware program (Compusyn,
Inc.) (Chou and Martin, 2005). Huh7.5.1 cells containing either GT 1b
or GT 3a were co-treated with grazoprevir and compounds 3, 9 and 10,
and CI values were calculated (Table 4). The CI values of compounds at
EC50 and EC75 were less than or equal to 1. The results indicated that
the co-treatment effects were either synergic or additive. These sy-
nergistic and additive effects likely attributed to the two different me-
chanisms of actions (proteinase inhibition and replication inhibition)
executed against the two distinct target molecules (NS3/4A and NS5A,
respectively) in the compound co-treatments.
3.5. Molecular docking analysis
We performed molecular docking analyses using the models of
NS5A domain I, open model (1ZH1-based model) (Tellinghuisen et al.,
2005) and closed-model (3FQQ-based model) (Love et al., 2009), in-
cluding the N-terminal amphipathic helix. To understand why com-
pound 10 had a stronger anti-viral effect than compound 3 against GT
1b HCV containing double mutations in NS5A, we analyzed the docking
models of compounds 3 and 10 inside the closed form of dimeric GT 1b
HCV NS5A (A/B) containing the double mutant (L31V/Y93H).
Figure S5A represents the docked model of compound 3 inside
closed-model (glide docking score = −6.26 kcal/mol) (Love et al.,
2009). 9,9-dibutyl-9H-fluorene core of compound 3 interacted with the
binding pocket residues (A:Cys57, A:Gly60, A:Ala61, A:ILE63, B:Thr56,
B:Ala61) of NS5A through van der Waals interaction. Val31 of subunit
A showed pi-alkyl interaction with one of the proline ring and alkyl-
alkyl interaction with terminal methyl of ester moiety. His93 of subunit
A showed pi-alkyl and hydrogen bond interactions with methyl group
of ester and carbonyl oxygen of ester, respectively. Val31 of subunit B
showed pi-alkyl interaction with the phenyl of other end of compound
3. Ester amide ‘NH’ showed hydrogen bond interaction with Gln62 of
subunit A. Side chain of Gln54 in subunit A interacted via two hydrogen
bonds with proline amide ‘O’ and ‘NH’ of amide linker which connected
central core and proline. Ile63 of subunit A interacted with n-butyl on
central core, and His93 of subunit B interacted with the central core and
proline amide via van der Waals interaction.
Figure S5B represents the docked model of compound 10 inside
closed-model (glide docking score = −7.04 kcal/mol) (Love et al.,
2009). n-Butyl moiety at the central core of compound 10 interacted
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Fig. 3. Mutations in RAVs selected during inhibitor treatments. (A) Mutations in replicon GT 3a selected during treatment of compound 3 at 750 pM. (B)
Mutations in replicon GT 3a selected during treatment of compound 10 at 750 pM. (C) EC50 values of velpatasvir and compound 10 on pools of GT 3a replicon-
containing cells selected by treatment of daclatasvir (75 nM) or velpatasvir (7.5 nM).
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Fig. 4. Effects of co-treatment of grazoprevir and fluorene compounds on colony formations of Huh 7.5.1 cells containing subgenomic replicons. (A)
Effects of co-treatment of grazoprevir (EC90 = 2 nM) and compound 3 and 10 on the colony formation of Huh 7.5.1 cells containing a GT 1b replicon NK5.1-Gluc. (B)
Effects of co-treatment of grazoprevir (EC90 = 100 nM) and compound 3 and 10 on the colony formation of Huh 7.5.1 cells containing a GT 3a replicon S52-Feo.
Table 4
CI values of compounds with Grazoprevir (a NS3/4A inhibitor).
Compound Combination EC50CI value a, b EC75CI value a, c
GT 1b (NK5.1) GT 3a (S52) GT 1b (NK5.1) GT 3a (S52)
3 Grazoprevir 0.8 ± 0.04 0.6 ± 0.30 1.0 ± 0.13 0.8 ± 0.32
9 Grazoprevir 0.7 ± 0.17 0.6 ± 0.09 0.9 ± 0.18 0.7 ± 0.04
10 Grazoprevir 0.7 ± 0.09 1.0 ± 0.05 0.9 ± 0.12 0.9 ± 0.01
CI > 1, Antagonistic effect; CI < 1, Synergistic effect; CI ≒ 1, Additive effect.Results from three independent experiments in duplicate.
a The values depict mean and standard deviation.
b EC50 CI value, Effective concentration 50 percent combination index value.
c EC75 CI value, Effective concentration 75 percent combination index value.
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with Ala61 of subunit A via alkyl-alkyl and with A:Thr55, A:Gly60,
A:Ile63, A:Thr95, B:Thr56, B:Gly60, and B:Ala61 via van der Waals
interactions. The 4-hydroxyl-L-proline moiety of compound 10 inter-
acted with A: Cys57 and B: His93 of NS5A via two hydrogen bonds.
The areas in NS5A interacting with inhibitors were predicted to be
similar to those predicted by previous docking study of daclatasvir in-
side closed-model (Love et al., 2009) that suggested residues Leu31,
Pro32, Val34, Ile52, Gln54, Thr56, Gly60, Gln62, Tyr93, Thr95, and
Pro97 participated in complex formation with the inhibitor (Ascher
et al., 2014). However, the detailed residues and chemical bonds con-
tributing to the protein-inhibitor interactions differed from each other.
Through the molecular docking analyses we found that the closed
model fitted better than the open model in terms of the relationship
between predicted affinity and inhibitor efficacy and the effects of in-
hibitors on the double mutant HCV (see below).
4. Discussion
Over the last several years, remarkable progress has been made in
the development of DAAs against HCV, and several anti-HCV drugs are
currently available (Grebely et al., 2017; Zhang et al., 2016). However,
the uneven efficacies of drugs against various GTs of HCV and the
spontaneous generation of RAVs remain as unsolved issues in HCV
therapeutics (Raj et al., 2017). HCV has an error-prone RNA-dependent
RNA polymerase (RdRp) NS5B, which shows no proofreading activity
during the RNA polymerization reaction (Poch et al., 1989). Therefore,
HCV variants (quasispecies) can quickly generate following HCV cul-
tivation for several generations, even if they originated from a single
clone. Upon anti-HCV compound treatment, compound-sensitive HCV
variants are unable to replicate. However, drug-resistant variants ex-
isting in a minor proportion replicate continuously, even in the pre-
sence of an anti-HCV drug, and quickly expand to large populations.
The genetic resistance barrier of a particular compound can be mon-
itored by measuring the colony-forming efficiency of replicon-con-
taining cells in the presence of the compound (Wang et al., 2012). For
example, Huh7.5.1 cells containing a variant of HCV replicon resistant
to an anti-HCV compound will grow even in the presence of the com-
pound and Geneticin (G418) since HCV replicon RNAs contain the
neomycin-resistance gene (NeoR in Fig. 1A).
Efforts have been made to create new NS5A inhibitors for anti-HCV
drug therapy. Previously, we reported highly effective fluorene com-
pounds against GT 1b. To improve the efficacy of compounds against
GT 3 and RAVs of HCV GT 1b, we modified residues at the R, Y, and Z
positions of compound 43 that was reported previously (Bae et al.,
2015) (Fig. 1B). The length of alkyl chains at the C9 of fluorene (R
position) affected the anti-HCV activity of compounds to GT 1b, GT 3a,
and RAVs of GT 1b. Compounds containing 9,9-dibutylfluorene and
9,9-dipentylfluorene cores (compounds 3 and 4, respectively) showed
very strong inhibitory effects against wild type GT 1b, wild type GT 3a,
and RAVs L31V of GT 1b (Table 2). We further modified the compounds
3 and 4 to improve anti-HCV effects. In this study, we focused on the L-
proline residues of compounds (Y and Z positions in Fig. 1B) since L-
proline substitutions with 4-oxo-L-proline (Bae et al., 2015) or 4-spir-
ocyclic ketal-L-proline (Kazmierski et al., 2014) improved anti-viral
effects against wild type HCV or RAVs, respectively (Table 3 and S1).
Particularly, substitutions of L-proline to 4-spirocyclic ketal-L-proline
(compounds 6, 8, 9, 12, 14, and 15) or 4-hydroxyl-L-proline (com-
pound 10) improved the efficacy of compounds against RAVs Y93H and
L31 + Y93H (Table 3 and S1). These results suggest that the L-proline
residues of compounds may localize in the vicinity of residue 93 (Y93)
of NS5A and that both 4-spirocyclic ketal-L-proline and 4-hydroxyl-L-
proline may allow binding of compounds to the histidine at residue 93.
The colony-forming efficiencies of Huh7.5.1 cells containing a GT
3a replicon showed peculiar patterns after anti-HCV compound treat-
ment. Compound 3 showed higher inhibitory effects than compound 10
in drug-resistant colony formation assays at low concentrations (75
pM). In contrast, compound 10 showed higher inhibitory effects at high
concentrations (7.5 nM or higher) (Fig. 2C). The higher efficacy of
compound 3 at low concentrations is likely attributed to the lower EC50
value of compound 3 than compound 10 (16 pM vs. 133 pM in Table 3).
Further, the higher efficiency of compound 10 at the high concentration
is likely attributed to the higher activity of compound 10 against RAVs,
such as Y93H and L31V + Y93H. These data clearly demonstrate that
the general efficacy of a compound (EC50) differs from the genetic re-
sistance barrier of the compound. As such, compound 3 is more effec-
tive than compound 10 against wild types of GT 1b and GT 3a; yet, the
genetic resistance barrier of compound 10 is higher than compound 3
against GT 3a. Importantly, the genetic resistance barrier of compound
10 is higher than velpatasvir, which is a second generation NS5A in-
hibitor, against GT 3a (compare Fig. 2C with Fig. S2B).
Moreover, compound 10 effectively inhibited a pool of GT 3a re-
plicons which were selected by treatment of velpatasvir (7.5 nM). The
EC50's of compound 10 and velpatasvir against these GT 3a RAVs were
0.74 and 14.3 nM, respectively (Fig. 3C). Compounds possessing high
genetic resistance barriers such as compound 10 are good candidates
for developing an anti-HCV drug for patients who were not successfully
treated with currently available drugs.
To minimize the RAV issue of anti-HCV drugs, combined treatment
with compounds having different mechanisms of action and different
target molecules is recommended (Polish Group of Experts for et al.,
2017). In this regard, we observed synergistic and/or additive effects of
anti-NS5A compounds (compounds 3, 9, and 10) with grazoprevir
(NS3/NS4A proteinase inhibitor) (Fig. 4). In practical applications,
however, co-treatment of compound 10 and another NS3/4A inhibitor
is recommendable for treatment of GT 3a since grazoprevir is not re-
commended for treating GT 3a (Sulejmani and Jafri, 2018).
We performed molecular docking analyses using the models of the
NS5A domain I, including the N-terminal amphipathic helix, to un-
derstand the molecular bases of anti-HCV activities of compounds 3 and
10, and the higher efficacy of compound 10 relative to compound 3 to
RAVs. Experimental results fitted better with the closed-model (3FQQ-
based model) (Tellinghuisen et al., 2005) than the open model (1ZH1-
based model) (Love et al., 2009). In general, predicted binding affinities
of inhibitors (compounds 3, 10) to wild type HCV were higher than to
double mutant HCV when the closed model was used (Fig. S5C). These
results correlate well with higher efficacies of these compounds to wild
type than to mutant HCV (Table 3). Moreover, the rank of predicted
affinities of inhibitors to double mutants fitted well with the rank of
efficacies of inhibitors to mutant HCV when the closed model was used
(Table 3 and Fig. S5C). However, the relationship between predicted
affinity and inhibitory efficacy did not match well with wild type HCV,
which is extremely sensitive to the compounds. This may indicate that
the affinity prediction by the molecular docking is useful for rough
estimation of efficacies of compounds with a wide range of efficacy (58
pM–41 nM), but not so useful for precise efficacy estimation of com-
pounds with subtle difference in efficacies (2–29 pM). The limitation of
affinity predictability of the molecular docking is likely attributed, at
least in part, to the uncertainty of the real structure of NS5A.
Addition of 4-hydroxyl group at the C4-position of L-proline (com-
pound 10) resulted in much stronger anti-viral activity than that of
unmodified L-proline (compound 3) against double mutant GT 1b
(EC50 = 58 pM vs. 41 nM). According to the molecular docking ana-
lysis, compounds 10 and 3 had glide docking scores of−7.04 kcal/mol
and −6.26 kcal/mol, respectively. Two more hydrogen bonds to the
double mutant were possible for compound 10 compared with com-
pound 3. One of them was a hydrogen bond between the hydroxyl
group at the C4 position of L-proline and histidine 93, a resistance-
associated substitution, which is depicted by a red circle in Fig. S5B.
These additional interactions likely contribute to the strong inhibitor
binding and high activity of compound 10 to double mutant HCV.
In conclusion, we developed NS5A inhibitors containing a fluorene
proline-amide skeleton and the structure-activity relationships of the
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compounds were analyzed. Moreover, we investigated the molecular
bases of the inhibitory activities of some compounds by the molecular
docking method. Through these approaches, we developed a compound
(designated as compound 10) that is very effective against GT 1b, GT 3,
and RAVs of GT 1b. This compound showed no cytotoxicity, very low
drug-drug interaction issues (determined by CYP inhibition test), and
no cardiotoxicity (determined by hERG ligand binding assays) (Tables
S2 and S3). Further investigations are in progress to improve the phy-
sicochemical property of compound 10.
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Abbreviations
HCV Hepatitis C virus
DAA direct-acting antiviral
SVR sustained virologic response
Peg-IFNα pegylated interferon α
NS5A hepatitis C virus nonstructural protein 5A
pM Picomolar
nM Nanomolar
EC50 Effective concentration 50%
CC50 cytotoxic concentration 50%
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